A 52-year-old man came to see me last spring about erectile dysfunction. He had been put on a PDE5 inhibitor by his primary care physician three years earlier, and it had stopped working as well over the past year. Nobody had checked his blood pressure standing versus sitting. Nobody had looked at his lipid panel beyond total cholesterol. Nobody had measured a morning testosterone, much less a free testosterone or estradiol. The conversation had been: here is the prescription, take it before sex, see you next year.
When I evaluate someone for sexual dysfunction, the first thing I am thinking about is the vasculature. The penis is a vascular organ. Arousal in women is a vascular event. The same arteries that supply the heart, the brain, and the kidneys supply the genitals — and the smaller-caliber vessels in the genitals are usually the first to show damage. Sexual dysfunction is, very often, the earliest clinical sign of cardiovascular disease, and the seventeen years I spent in emergency medicine and the cardiac ICU made that connection impossible to ignore.
Why the genitals show vascular disease before the heart does
The arteries that fill the corpora cavernosa in men are roughly 1 to 2 millimeters in diameter. The coronary arteries are 3 to 4 millimeters. The carotids are 5 to 7 millimeters. Endothelial dysfunction — the early stage of atherosclerosis where the vessel lining loses its ability to vasodilate normally — affects all of these arteries at the same time, but the symptom shows up first in the smallest vessels because they have the least margin to lose.
This is not a marketing line. It is well-documented in the cardiology literature. Men with new-onset erectile dysfunction have a measurably elevated risk of a major cardiovascular event in the next three to five years compared to age-matched men without ED. The functional translation of that data: when a man in his forties or fifties presents with worsening erections, the right next step is not a higher dose of sildenafil. The right next step is a vascular workup.
In women, the same biology operates. Genital arousal — engorgement of the clitoris and vaginal walls, lubrication, sensitivity — depends on intact endothelial function in the pelvic vasculature. Reduced arousal and reduced lubrication in midlife are partly hormonal (declining estrogen affects tissue quality directly), but they are also partly vascular. The conversation with women rarely gets to the vascular piece because the hormonal piece is loud enough to dominate it.
The mechanism in plain language
Both erection in men and genital arousal in women depend on a nitric oxide–mediated cascade. Sexual stimulation triggers nerve endings to release nitric oxide. Nitric oxide diffuses into the smooth muscle of the vessel wall and activates an enzyme called guanylate cyclase, which produces cyclic GMP. Cyclic GMP relaxes the smooth muscle, the vessels dilate, blood flows in, the tissue engorges. PDE5 inhibitors — sildenafil, tadalafil — work by blocking the enzyme that breaks down cyclic GMP, prolonging the vasodilation.
What that mechanism requires: a healthy endothelium that produces nitric oxide on demand, smooth muscle that responds to nitric oxide, vessels that are not stiff or plaque-laden, and adequate testosterone (in men) or estrogen (in women) to maintain the smooth muscle and tissue quality the cascade depends on.
Anything that damages the endothelium — diabetes, hypertension, dyslipidemia, smoking, chronic inflammation, sleep apnea, sedentary deconditioning — degrades the cascade. Hormonal decline degrades it from a different angle. Most of the patients I see have some combination of both.
What I look for in the workup
When a patient presents with sexual dysfunction, the workup I do is broader than what most patients have had before. I want a full lipid panel including ApoB and Lp(a), not just total cholesterol and LDL. I want fasting glucose and a hemoglobin A1c. I want a comprehensive metabolic panel and a CBC. I want an inflammatory marker — usually high-sensitivity CRP. I want a complete hormone panel: total and free testosterone, SHBG, estradiol, LH, FSH, DHEA-S, prolactin, and TSH with free T3 and free T4.
I check resting blood pressure and orthostatic readings. I review every medication and every supplement. SSRIs, beta-blockers, finasteride, certain antihistamines, and PPIs all have well-documented effects on sexual function — and the prescribing clinicians often did not warn the patient about it. I ask about sleep, snoring, and witnessed apnea, because untreated sleep apnea drops testosterone and damages the endothelium silently for years.
For women, I add the same hormonal panel plus progesterone where appropriate, and I take a careful history about vaginal dryness, dyspareunia, and arousal versus libido — those are different problems with different solutions.
Not sure where to start?
The Start Here pathway walks you through the most common entry points and helps you decide which consultation type is the right fit. Five minutes of self-assessment can save you a wrong-direction conversation.
The point of all of this is that "ED" or "low libido" is a symptom, not a diagnosis. The actual diagnosis is whatever combination of vascular, hormonal, neurological, and pharmacological factors is producing the symptom. You cannot treat what you have not identified.
Building a real treatment plan
Once the workup is in hand, the plan addresses what the data shows. In a man with low free testosterone, elevated SHBG, and early endothelial dysfunction, men's hormone therapy is part of the answer — not because hormone therapy treats vascular disease directly, but because adequate testosterone is required for the nitric oxide cascade to function properly. Testosterone optimization, properly dosed and monitored, often improves erectile function in men whose ED was hormonally driven.
If the vascular component is significant, the conversation has to include lifestyle interventions that actually move the needle on endothelial function — structured exercise, weight optimization, glycemic control, sleep apnea evaluation, and where appropriate, lipid-lowering therapy. PDE5 inhibitors are still in the toolkit, but they are not the whole toolkit, and a patient whose underlying vascular disease is progressing will outrun the medication.
For tissue-quality issues — particularly in women presenting with arousal disorder, decreased sensitivity, urinary changes, or recurrent UTIs — the O-Shot is a regenerative option. PRP injected into specific anatomic locations of the clitoris and anterior vaginal wall delivers concentrated growth factors to tissue that has thinned with hormonal decline. The mechanism is genuine: platelet-derived growth factors recruit local stem cells and stimulate angiogenesis, building new microvasculature in tissue that has lost it. The honest version is that response varies — some patients have dramatic improvement, others have modest improvement, a small number do not respond meaningfully. We track response and adjust.
For men with vascular ED who are not responding to medication, ED treatment at the practice includes regenerative options as well, with similar honest expectations.
For women whose primary issue is hormonal, hormone optimization — with attention to estradiol, progesterone, and often testosterone — addresses the substrate that the vascular and tissue work depends on.
How I evaluate a patient at the first visit
The first visit is a conversation, not a procedure. I allocate time. I ask the questions that should have been asked years ago. I do not rush to a treatment recommendation in the first hour because the workup has not happened yet, and any recommendation made without the workup is a guess.
I look for patterns. A 48-year-old man with worsening erections, central adiposity, snoring, mild fatigue, and an LDL of 145 is not an ED patient. He is a metabolic and vascular patient who happens to be presenting through his sexual function. The right plan addresses the metabolic and vascular picture, which will incidentally address the ED. Treating only the ED in that patient is treating the dashboard light without checking the engine.
A 51-year-old woman with reduced libido, vaginal dryness, sleep disruption, and three months of irregular periods is not a libido patient. She is a perimenopausal patient whose libido is one symptom of a hormonal transition that needs to be addressed comprehensively. The O-Shot may eventually be part of her plan, but the hormonal evaluation comes first.
Where to start if this describes you
If you are reading this because you recognize yourself in it, the starting point is a comprehensive workup — labs, history, full medication review, and a real conversation about what is happening. The sexual dysfunction conversation is the hardest one most patients have ever had with a clinician, which is exactly why it is worth having with somebody who is going to take the time and look at the whole picture.
Book the private consultation directly, or call either the Columbus or Warner Robins clinic and ask for a sexual wellness consultation specifically — the front desk will allocate the right block of time and route you to the right intake. Bring any lab work you have had in the past two years, a full medication list, and the questions you have been afraid to ask. We will start there.
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Individual clinical decisions should be made in consultation with a qualified healthcare provider following appropriate evaluation. References to specific treatments, dosing, or protocols are informational.
Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.
Ready to talk it through with a clinician?
Book online or call either Georgia location. Every visit starts with a consultation.